Immunologic benefits of enfuvirtide in patients enrolled in a drug assistance program

Annals of Pharmacotherapy

Volumn 42, Issue 5, 2008, Pages 621-626

  Saberi, Parya ^a,c   Caswell, Nikolai H ^b   Gruta, Cristina I ^a   Tokumoto, Jason N ^a   Dong, Betty J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Box 1365 ^*

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD4+ cell count; Enfuvirtide; Viremia

Indexed keywords

CD4 ANTIGEN; ENFUVIRTIDE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG DOSE REGIMEN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RNA ANALYSIS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FOLLOW-UP STUDIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; STATE HEALTH PLANS; VIRAL LOAD;

EID: 42949101223     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K572     Document Type: Article

References (11)